A Study of Nilotinib in Adult Patients With Imatinib Resistant or -

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Completed	`NCT02057185` - Occupational Status and Hematological Disease
Recruiting	`NCT03326310` - Selumetinib and Azacitidine in High Risk Chronic Blood Cancers	Phase 1
Recruiting	`NCT04621851` - Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Completed	`NCT01207440` - Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)	Phase 2
Not yet recruiting	`NCT06409936` - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML	Phase 2
Active, not recruiting	`NCT02917720` - 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients	Phase 2
Not yet recruiting	`NCT02883036` - Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia	N/A
Withdrawn	`NCT01188889` - RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.	Phase 1/Phase 2
Completed	`NCT01795716` - Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body	Phase 1
Completed	`NCT00988013` - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies	N/A
Approved for marketing	`NCT00905593` - Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase	Phase 3
Terminated	`NCT00573378` - Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia	Phase 2
Completed	`NCT00469014` - Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia	Phase 2
Terminated	`NCT00522990` - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias	Phase 1/Phase 2
Unknown status	`NCT00598624` - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)	Phase 2
Completed	`NCT00257647` - Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)	N/A
Completed	`NCT00219739` - STI571 ProspectIve RandomIzed Trial: SPIRIT	Phase 3
Completed	`NCT06148493` - Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Completed	`NCT00375219` - Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation	Phase 2

NCT number	NCT01126892
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	January 2009
Completion date	April 2011

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase — ENACT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms